Abstract
Background: We performed a critical overview of published systematic reviews (SRs) of chemotherapy for advanced and locally advanced pancreatic cancer, and evaluated their quality using AMSTAR2 and ROBIS tools.
Materials and Methods: PubMed and Cochrane Central Library were searched for SRs on 13th June 2020. SRs with meta-analysis which included only randomized controlled trials and that had assessed chemotherapy as one of the treatment arms were included. The outcome measures, which were looked into, were progression-free survival (PFS), overall survival (OS), and adverse events (AEs) of grade 3 or above. Two reviewers independently assessed all the SRs with both ROBIS and AMSTAR2.
Results: Out of the 1,879 identified records, 26 SRs were included for the overview. Most SRs had concluded that gemcitabine-based combination regimes, prolonged OS and PFS, but increased the incidence of grade 3-4 toxicities when compared to gemcitabine monotherapy, but survival benefits were not consistent when gemcitabine was combined with molecular targeted agents. As per ROBIS, 24/26 SRs had 'high' risk of bias, with only 1/26 SR having 'low' risk of bias. As per AMSTAR2, 25/26 SRs had 'critically low', and 1/26 SR had 'low' confidence in the results. The study which scored 'low risk of bias' in ROBIS scored ‘low confidence in results’ in AMSTAR2. The inter- rater reliability for scoring the overall confidence in the SRs with AMSTAR2 and the overall domain in ROBIS was substantial; ROBIS: kappa=0.785, SEM=0.207, p<0.001; AMSTAR2: kappa= 0.649, SEM=0.323, p<0.001.
Conclusion: Gemcitabine-based combination regimens can prolong OS and PFS but also worsen AEs when compared to gemcitabine monotherapy. The included SRs have an overall low methodological quality and high risk of bias as per AMSTAR2 and ROBIS respectively.
Keywords: AMSTAR2, ROBIS, pancreatic cancer, systematic review, methodological quality, risk of bias.
Graphical Abstract
[1]
Zhang Q, Zeng L, Chen Y, et al. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract 2016; 20168962321[http://dx.doi.org/10.1155/2016/8962321] [PMID: 26941789]
[2]
Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014; 14: 471.[http://dx.doi.org/10.1186/1471-2407-14-471] [PMID: 24972449]
[3]
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9694-705.[http://dx.doi.org/10.3748/wjg.v22.i44.9694] [PMID: 27956793]
[4]
National Cancer Institute. Surveillance, Epidemiology and ERP Pancreatic Cancer - Cancer Stat Facts 2019. Available from:
https://seer.cancer.gov/statfacts/html/pancreas.html
[5]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7-30.[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[6]
Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ 2012; 344e2476[http://dx.doi.org/10.1136/bmj.e2476] [PMID: 22592847]
[7]
Yang Z-Y, Yuan J-Q, Di M-Y, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One 2013; 8(3)e57528[http://dx.doi.org/10.1371/journal.pone.0057528] [PMID: 23472089]
[8]
Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-58.[http://dx.doi.org/10.3748/wjg.v18.i35.4944] [PMID: 23002368]
[9]
Li D, Chen C, Zhou Y, et al. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94(35)e1345[http://dx.doi.org/10.1097/MD.0000000000001345] [PMID: 26334891]
[10]
Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17(6): 801-10.[http://dx.doi.org/10.1016/S1470-2045(16)00172-8] [PMID: 27160474]
[11]
Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6): 2403-13.[http://dx.doi.org/10.1200/JCO.1997.15.6.2403] [PMID: 9196156]
[12]
Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6(6): 369-76.[http://dx.doi.org/10.1016/S1470-2045(05)70175-3] [PMID: 15925814]
[13]
Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817-25.[http://dx.doi.org/10.1056/NEJMoa1011923] [PMID: 21561347]
[14]
Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15): 1960-6.[http://dx.doi.org/10.1200/JCO.2006.07.9525] [PMID: 17452677]
[15]
Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62(10): 1013-20.[http://dx.doi.org/10.1016/j.jclinepi.2008.10.009] [PMID: 19230606]
[16]
Whiting P, Savović J, Higgins JPT, et al. ROBIS group. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 2016; 69: 225-34.[http://dx.doi.org/10.1016/j.jclinepi.2015.06.005] [PMID: 26092286]
[17]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.[http://dx.doi.org/10.1136/bmj.b2700] [PMID: 19622552]
[18]
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283(15): 2008-12.[http://dx.doi.org/10.1001/jama.283.15.2008] [PMID: 10789670]
[19]
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008.[http://dx.doi.org/10.1136/bmj.j4008] [PMID: 28935701]
[20]
Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: Measures of agreement. Perspect Clin Res 2017; 8(4): 187-91.[http://dx.doi.org/10.4103/picr.PICR_123_17] [PMID: 29109937]
[21]
Li Y, Sun J, Jiang Z, Zhang L, Liu G. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother 2015; 27(4): 227-34.[http://dx.doi.org/10.1179/1973947815Y.0000000013] [PMID: 25790948]
[22]
Liu Y, Huang QK, Hong WD, Wu JM, Sun XC. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile. Clin Res Hepatol Gastroenterol 2015; 39(2): 254-60.[http://dx.doi.org/10.1016/j.clinre.2014.08.012] [PMID: 25304193]
[23]
Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Jpn J Clin Oncol 2015; 45(12): 1122-30.[http://dx.doi.org/10.1093/jjco/hyv141] [PMID: 26518328]
[24]
Xie R, Liang HL, Wang Y, Guo SS. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Dig Dis 2006; 7(1): 49-54.[http://dx.doi.org/10.1111/j.1443-9573.2006.00244.x] [PMID: 16412038]
[25]
Jin SF, Fan ZK, Pan L, Jin LM. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. HBPD INT 2017; 16(3): 236-44.[http://dx.doi.org/10.1016/S1499-3872(17)60022-5] [PMID: 28603091]
[26]
Tu C, Zheng F, Wang JY, Li YY, Qian KQ. An updated meta-analysis and system review: is Gemcitabine+ Fluoropyrimidine in combination a better therapy versus gemcitabine alone for advanced and unresectable pancreatic cancer? Asian Pac J Cancer Prev 2015; 16(14): 5681-6.[http://dx.doi.org/10.7314/APJCP.2015.16.14.5681] [PMID: 26320435]
[27]
Li Q, Yan H, Liu W, Zhen H, Yang Y, Cao B. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014; 9(8)e104346[http://dx.doi.org/10.1371/journal.pone.0104346] [PMID: 25093849]
[28]
Hu J, Zhao G, Wang HX, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011; 4(1): 11.[http://dx.doi.org/10.1186/1756-8722-4-11] [PMID: 21439076]
[29]
Xie DR, Yang Q, Chen DL, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 2010; 40(5): 432-41.[http://dx.doi.org/10.1093/jjco/hyp198] [PMID: 20147334]
[30]
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8(1): 82.[http://dx.doi.org/10.1186/1471-2407-8-82] [PMID: 18373843]
[31]
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Target Oncol 2017; 12(3): 309-21.[PMID: 28353074]
[32]
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. Dig Liver Dis 2014; 46(5): 452-9.[http://dx.doi.org/10.1016/j.dld.2014.01.001] [PMID: 24565950]
[33]
Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013; 49(3): 593-603.[http://dx.doi.org/10.1016/j.ejca.2012.08.019] [PMID: 22989511]
[34]
Banu E, Banu A, Fodor A, et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 2007; 24(10): 865-79.[http://dx.doi.org/10.2165/00002512-200724100-00006] [PMID: 17896834]
[35]
Bria E, Milella M, Gelibter A, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007; 110(3): 525-33.[http://dx.doi.org/10.1002/cncr.22809] [PMID: 17577216]
[36]
Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006; 12(43): 6973-81.[http://dx.doi.org/10.3748/wjg.v12.i43.6973] [PMID: 17109519]
[37]
Ottaiano A, Capozzi M, De Divitiis C, et al. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Acta Oncol 2017; 56(3): 377-83.[http://dx.doi.org/10.1080/0284186X.2017.1288922] [PMID: 28256961]
[38]
Chen L, Zhang M, Luo S. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumour Biol 2014; 35(11): 11551-8.[http://dx.doi.org/10.1007/s13277-014-2451-6] [PMID: 25129442]
[39]
Li Q, Yuan Z, Yan H, Wen Z, Zhang R, Cao B. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Clin Ther 2014; 36(7): 1054-63.[http://dx.doi.org/10.1016/j.clinthera.2014.05.066] [PMID: 24986485]
[40]
Tian W, Ding W, Kim S, Xu X, Pan M, Chen S. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. Pancreatology 2013; 13(4): 415-22.[http://dx.doi.org/10.1016/j.pan.2013.04.195] [PMID: 23890141]
[41]
Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford) 2012; 14(4): 260-8.[http://dx.doi.org/10.1111/j.1477-2574.2012.00441.x] [PMID: 22404265]
[42]
Ciliberto D, Staropoli N, Chiellino S, Botta C, Tassone P, Tagliaferri P. Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology 2016; 16(2): 249-58.[http://dx.doi.org/10.1016/j.pan.2016.01.003] [PMID: 26852170]
[43]
Xie J, Yuan J, Lu L. Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials. Diagn Pathol 2014; 9(1): 214.[http://dx.doi.org/10.1186/s13000-014-0214-8] [PMID: 25421173]
[44]
Zhong S, Qie S, Yang L, Yan Q, Ge L, Wang Z. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore) 2017; 96(30)e7611[http://dx.doi.org/10.1097/MD.0000000000007611] [PMID: 28746215]
[45]
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25(18): 2607-15.[http://dx.doi.org/10.1200/JCO.2006.09.2551] [PMID: 17577041]
[46]
Pieper D, Puljak L, González-Lorenzo M, Minozzi S. Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol 2019; 108: 26-33.[http://dx.doi.org/10.1016/j.jclinepi.2018.12.004] [PMID: 30543911]
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
17